Jacc-hf study compares daxor's bva-100® volume metric to cardiomems® pressure metric in heart failure patients

Volume and pressure measures are complementary, not interchangeable oak ridge, tn, july 12, 2023 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces a new research letter in the journal of the american college of c ardiology – heart failure validating the benefits of the company's bva-100 diagnostic in optimizing individualized therapy for heart failure patients. the study, titled “discordant pressure-volume trends during cardiomems monitoring,” evaluated the correlation of pressure-volume profiles over two time periods in a series of heart failure (hf) patients who underwent cardiomems implantation to measure pressure, and direct measurement of total blood volume using daxor's blood volume analysis (bva) diagnostic.
DXR Ratings Summary
DXR Quant Ranking